Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614755 | 0.85 | GRM5 (0.39) | GRM5CYP2D6 | |
| SCHEMBL17552563 | 0.80 | GRM5 (0.50) | GRM5KCNH2CYP2D6MAOB | |
| SCHEMBL30707869 | 0.80 | KCNH2 (0.67) | GRM5KCNH2CYP2D6MAOB | |
| SCHEMBL4562631 | 0.80 | KCNH2 (0.67) | GRM5KCNH2CYP2D6MAOB | |
| SCHEMBL852832 | 0.79 | TSHR (0.38) | GRM5 | |
| Charcoal, Activated SCHEMBL31286308 | 0.78 | KCNH2 (0.64) | GRM5KCNH2CYP2D6MAOB | |
| SCHEMBL23867871 | 0.78 | APP (0.50) | GRM5KCNH2CYP2D6 | |
| SCHEMBL31349195 | 0.78 | GRM5 (0.56) | GRM5 | |
| SCHEMBL3347354 | 0.78 | GRM5 (0.56) | GRM5 | |
| SCHEMBL2697031 | 0.77 | KCNH2 (0.58) | GRM5KCNH2CYP2D6MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119117-A | Method for preparing alkynyl phosphonate by mechanochemical method | 贵州民族大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-111961052-B | Preparation method of gamma-carboline derivative | 沈阳师范大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-111961052-A | Preparation method of gamma-carboline derivative | 沈阳师范大学 | 2020-11-20 | — | — | CN | disclosed |
| US-9296687-B2 | Modulators of HSP70/DnaK function and methods of use thereof | FOX CHASE CANCER CENTER (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296687-B2 | Modulators of HSP70/DnaK function and methods of use thereof | FOX CHASE CANCER CENTER (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140087005-A1 | MODULATORS OF HSP70/DNAK FUNCTION AND METHODS OF USE THEREOF | FOX CHASE CANCER CENTER (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140087005-A1 | MODULATORS OF HSP70/DNAK FUNCTION AND METHODS OF USE THEREOF | FOX CHASE CANCER CENTER (US) | 2014-03-27 | — | — | US | disclosed |
| EP-1425010-B8 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICALS INC (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1425010-B1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110189125-A1 | Modulators of HSP70/DnaK Function and Methods of Use Thereof | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-08-04 | — | — | US | disclosed |
| US-7241760-B2 | Central nervous system disorders; psycholgical disorders; antiepi;eptic agents; schizophrenia; Alzheimer's disease; cognition activators; analgesics | HOFFMANN-LA ROCHE INC. (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1670784-A1 | HETEROARYL-SUBSTITUTED IMDAZOLE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6855722-B2 | Substituted indoles and their use as integrin antagonists | DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| WO-2004111040-A1 | HETEROARYL-SUBSTITUTED IMDAZOLE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20040254179-A1 | Heteroaryl-substituted imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-16 | — | — | US | disclosed |
| EP-1425010-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002060438-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189125-A1 | Modulators of HSP70/DnaK Function and Methods of Use Thereof | HSPBP1, HSPE1, HSP90B1 | GRM5 4458/4885KCNH2 4502/4885CYP2D6 4519/4885 |
| US-20040254179-A1 | Heteroaryl-substituted imidazole derivatives | GRIN2A, GRIN2B, GRIK5 | GRM5 4/4885KCNH2 167/4885CYP2D6 994/4885 |
| US-20140087005-A1 | MODULATORS OF HSP70/DNAK FUNCTION AND METHODS OF USE THEREOF | HSPBP1, HSPE1, HSP90B1 | GRM5 4458/4885KCNH2 4502/4885CYP2D6 4519/4885 |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | GRM5 600/4885KCNH2 387/4885CYP2D6 2523/4885 |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGAL, ITGA5 | GRM5 554/4885KCNH2 467/4885CYP2D6 2465/4885 |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | GRM5 570/4885KCNH2 357/4885CYP2D6 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.